Polaris Market Research
Human Growth Hormone Market Size, Industry Growth Report, 2025-2034
Inquire Before Buying Request Free Sample
Human Growth Hormone Market Size, Industry Growth Report, 2025-2034

Human Growth Hormone Market Size, Share, Trends, & Industry Analysis Report

By Type (Long-acting, Short-acting & Intermediate-acting), By Route of Administration, By Age, By Disease, By Distribution Channel, and By Region – Market Forecast, 2025–2034

  • Published Date:Oct-2025
  • Pages: 122
  • Format: PDF
  • Report ID: PM4705
  • Base Year: 2024
  • Historical Data: 2020-2023

Overview

The human growth hormone market size was valued at USD 6.49 billion in 2024, growing at a CAGR of 8.4% from 2025–2034. Key factors driving demand is rising prevalence of growth hormone deficiency disorders, and expanding healthcare infrastructure in emerging regions.

Key Insights

  • The long-acting segment is expected to grow at a CAGR of 9.3% during the forecast period, driven by its ability to enhance patient adherence and convenience.
  • In 2024, the online pharmacies segment captured a significant revenue share of 14.66%, as online pharmacies are rapidly becoming a popular channel for distributing human growth hormone, especially following the pandemic.
  • North America accounted for 39.18% of the global human growth hormone market revenue in 2024, supported by advanced healthcare infrastructure, high awareness of growth disorders, and substantial spending on specialty drugs.
  • Within North America, the U.S. dominated with an 80.67% revenue share in 2024, attributed to early diagnosis, broad healthcare access, and a high rate of hormone deficiency treatments.
  • The Asia Pacific market is projected to grow at a CAGR of 9.8% over the forecast period, driven by increasing awareness of hormone disorders and improvements in healthcare infrastructure.

Industry Dynamics

  • Rising prevalence of growth hormone deficiency disorders are driving the demand for HGH.
  • Expanding healthcare infrastructure in emerging regions is driving the human growth hormone market
  • Advancements in recombinant DNA technology have led to the development of biosynthetic human growth hormone, reducing dependency on natural extraction and enabling large-scale production.
  • High treatment costs and stringent regulatory requirements restrain the widespread adoption.

Market Statistics

  • 2024 Market Size: USD 6.49 Billion
  • 2034 Projected Market Size: USD 14.51 Billion
  • CAGR (2025-2034): 8.4%
  • North America: Largest Market Share

AI Impact on Human Growth Hormone Market

  • AI enhances patient diagnosis by analyzing medical data to detect growth hormone deficiencies earlier and more accurately.
  • AI-driven personalized treatment plans improve dosing accuracy and patient outcomes, optimizing HGH therapy for individual needs.
  • AI-powered drug discovery and development accelerate the creation of new and improved HGH formulations, including long-acting therapies.
  • AI-based monitoring tools help track patient adherence and response to HGH treatment in real time, enabling timely adjustments and better management.
  • Predictive analytics using AI supports supply chain optimization, ensuring timely delivery and reducing costs in HGH distribution.

Human growth hormone is a protein hormone produced by the pituitary gland that stimulates growth, cell reproduction, and regeneration in humans. It plays a crucial role in childhood growth and continues to regulate body composition, muscle and bone growth, and metabolism in adults. Synthetic hGH is used to treat growth disorders in children and hormone deficiencies in adults.

Human Growth Hormone Market Size, By Region, 2020 - 2034 (USD Billion)

The industry is witnessing significant expansion owing to rising awareness regarding growth hormone deficiencies and their impact on human health. Human growth hormone, a peptide hormone secreted by the pituitary gland, plays a crucial role in stimulating growth, cell reproduction, and regeneration. Over the years, its use has expanded beyond treating hormonal deficiencies to include anti-aging therapies, athletic performance enhancement, and cosmetic applications, leading to broader penetration across various end-user segments.

Advancements in recombinant DNA technology have led to the development of biosynthetic human growth hormone, reducing dependency on natural extraction and enabling large-scale production. These innovations have significantly increased the availability and accessibility of HGH treatments. Additionally, the increasing number of pipeline products, improved drug delivery systems such as pen devices and auto-injectors, and the growing investments in biotechnology and pharmaceutical R&D are expected to further drive growth in the coming years.

The future scope also lies in its potential integration with personalized medicine and genomics. Ongoing research aimed at understanding individual hormone profiles and responses to HGH therapy could pave the way for customized treatment regimens that maximize efficacy while minimizing side effects. This precision-based approach is likely to gain traction as healthcare systems globally move towards more tailored and outcome-oriented treatments.

Drivers & Opportunities

Rising Prevalence of Growth Hormone Deficiency Disorders: The increasing number of people diagnosed with growth hormone deficiency, especially in children fuels the demand for the human growth hormone. GHD leads to short stature, delayed puberty, and other health issues, which often require long-term hormone therapy. Advances in medical diagnostics have made it easier to detect these conditions early. More patients are being diagnosed and treated as awareness grows. This drives demand for hGH therapies in both children and adults. More people are seeking treatment with better access to healthcare globally, further fueling the growth.

Expanding Healthcare Infrastructure in Emerging Regions: Countries in Asia, Latin America, and Africa are investing more in healthcare infrastructure. According to the Government of Australia’s Budget Australia, in 2025-26 Australian government has funded USD 644 million to expand Medicare Urgent Care Clinics and USD 7.9 billion to provide more bulk billing. Better hospitals, access to specialists, and improved diagnostic capabilities are enabling earlier detection and treatment of hormone deficiencies. Governments in these regions are further increasing funding for rare disease treatments and encouraging pharmaceutical investments. The demand for hGH products rises as awareness of growth disorders increases and more patients get access to medical care, thereby fueling the growth.

Human Growth Hormone Market Size Worth USD 14.51 Billion by 2034 | CAGR: 8.4%

Human Growth Hormone Company Sales Area & Product Type

Company Name

Sales Area

Product Type

AnkeBio Co., Ltd

APAC, and International
  • Ansomone-Human Growth Hormone for Injection

Ascendis Pharma

North America, Europe, and APAC
  • SKYTROFA
  • TransCon hGH

Eli Lilly and Company

North America and International
  • Humatrope

Ferring Pharmaceuticals

North America, Europe, and International
  • ZOMACTON (somatropin)

Segmental Insights

Type Analysis

Based on type, the segmentation includes long-acting, short-acting & intermediate-acting. Long-acting segment is projected to grow at a CAGR of 9.3% over the forecast period driven by its ability to improve patient adherence and convenience. These formulations are designed to reduce the frequency of injections from daily to weekly or even monthly doses, making them especially attractive for pediatric and adult patients undergoing long-term therapy. Long-acting HGH utilizes advanced drug delivery technologies such as sustained-release microspheres, PEGylation, or fusion proteins to prolong the hormone’s half-life in the body. This approach minimizes the physical and psychological burden of frequent injections, which is a major concern in pediatric endocrinology and chronic GHD management.

Route of Administration Analysis

Based on route of administration, the segmentation includes oral, and parenteral. Oral segment is expected to witness a significant share over the forecast period driven by the demand for non-invasive, user-friendly treatment options. Traditionally, HGH has faced bioavailability challenges when administered orally due to degradation by digestive enzymes and poor intestinal absorption. However, recent advancements in peptide delivery systems, such as encapsulation technologies, enzyme inhibitors, and absorption enhancers, are enabling the development of oral HGH formulations. These innovations aim to overcome the limitations of gastrointestinal degradation, allowing for systemic absorption and effective therapeutic action, thereby driving the segment growth.

Age Analysis

In terms of age, the segmentation includes pediatric, and adult. The adult held 53.09% of revenue share in 2024 as awareness around adult growth hormone deficiency (AGHD) continues to rise. Adults may require HGH therapy due to pituitary disorders, hypothalamic damage, or as a continuation of childhood GHD. Symptoms such as decreased muscle mass, fatigue, poor bone density, and impaired quality of life have driven greater recognition of AGHD as a treatable medical condition. Although historically underdiagnosed, adult GHD is now being addressed more actively through comprehensive hormone testing protocols and better physician education. Consequently, more adults are receiving timely intervention with HGH therapy to improve metabolic functions and overall well-being, thereby fueling the growth in the segment.

Distribution Channel Analysis

In terms of distribution channel, the segmentation includes hospital pharmacies, retail pharmacies & drug stores, and online pharmacies. The online pharmacies segment held significant revenue share in 2024, holding 14.66% as online pharmacies are emerging as a rapidly growing channel for human growth hormone distribution, especially in the post-pandemic era where telemedicine and digital health platforms have witnessed massive adoption. These platforms offer convenience, discretion, and home delivery services, which are particularly appealing for adult patients managing chronic conditions such as adult GHD or those undergoing long-term treatment for Turner syndrome or PWS. Online pharmacies also provide easy access to a wide range of HGH brands and biosimilars, along with competitive pricing and subscription-based refill models that enhance treatment adherence. Additionally, the rise of e-commerce in healthcare has prompted regulatory authorities to tighten norms around online sales of prescription-only medicines like HGH. As a result, legitimate online pharmacies are required to verify prescriptions, ensure temperature-controlled shipping, and comply with national drug safety regulations. Despite concerns over counterfeit or unauthorized products in the digital space, licensed online platforms with proper accreditation are gaining trust among patients and caregivers.

Human Growth Hormone Market By Type Analysis, 2020 - 2034 (USD Billion)

Regional Analysis

North America human growth hormone market accounted for 39.18% of global revenue share in 2024 due to advanced healthcare infrastructure, high awareness of growth disorders, and strong spending on specialty drugs. The region has a large number of diagnosed patients and a high adoption rate for innovative therapies, including long-acting formulations and biosimilars. Supportive reimbursement policies and ongoing R&D by major pharmaceutical companies further push the growth. The presence of leading players such as Pfizer and Eli Lilly ensures continuous product development and marketing efforts. Technological advancements and a focus on personalized medicine further boost growth across the region, thereby fueling the growth.

U.S. Human Growth Hormone Market Insight

The U.S. held 80.67% of the revenue share within North America in 2024, due to early diagnosis, widespread healthcare access, and a high rate of hormone deficiency treatments. The country has a robust pipeline of innovative hGH therapies, including gene-based and long-acting solutions. Government initiatives to treat rare pediatric diseases, along with insurance coverage for hGH therapies, make treatments more accessible. Additionally, rising off-label use of hGH for anti-aging also drives the demand, thereby fueling the growth.

Asia Pacific Human Growth Hormone Market

The market in Asia Pacific is expected to register a CAGR of 9.8% during the forecast period due to increasing awareness of hormone disorders and improvements in healthcare infrastructure. Countries in this region are investing more in diagnostics and rare disease treatment, leading to early detection of growth hormone deficiencies. Rising disposable incomes and urbanization have further led to higher healthcare spending. Governments are encouraging biosimilar adoption to make therapies affordable, and pharmaceutical companies are expanding operations to tap into this large population base. The growing pediatric population, combined with efforts to modernize healthcare systems boosts the growth in the region.

China Human Growth Hormone Market Overview

The demand in China is rising due to a large population, rising health awareness, and expanding access to modern healthcare. Government support for rare disease treatment and inclusion of hGH therapies in insurance schemes have made treatment more affordable. Chinese biotech firms, such as AnkeBio, are also active in producing cost-effective biosimilars for domestic use. Increasing demand for pediatric treatments, coupled with urbanization and improved healthcare coverage, drives growth. Additionally, investments in local R&D and clinical trials are helping bring innovative therapies to market faster, thereby driving the growth in the China.

Europe Human Growth Hormone Market

The industry in the Europe is projected to grow at a CAGR of 8.1% from 2025 to 2034, due to its well-established healthcare systems and high awareness of growth hormone disorders. Countries like Germany, France, and the UK have advanced diagnostic capabilities, enabling early detection and treatment. The region further supports the use of biosimilars, which helps reduce treatment costs and increases patient access. Regulatory support from the European Medicines Agency (EMA) encourages innovation while ensuring safety and quality. Additionally, aging populations and increasing adult growth hormone deficiency cases are boosting demand. Pharmaceutical companies are investing in localized production and R&D further driving the growth.

Human Growth Hormone Market Trends, by Region, 2020 – 2034 (USD Billion)

Key Players & Competitive Analysis

The industry is highly competitive, dominated by key global pharmaceutical and biotech players. Novo Nordisk A/S and Eli Lilly lead with well-established hGH therapies and strong R&D pipelines. Pfizer Inc., in partnership with OPKO Health, offers a long-acting growth hormone, enhancing market differentiation. Ascendis Pharma has gained traction with innovative long-acting formulations. Merck KGaA and F. Hoffmann-La Roche Ltd focus on biosimilar and next-generation therapies, while Sandoz Inc. and Teva Pharmaceuticals play significant roles in the biosimilar segment, increasing pricing pressure. Ferring Pharmaceuticals and AnkeBio Co., Ltd expand regional presence, especially in Asia. The market is driven by technological advancements, long-acting formulations, and increasing pediatric and adult growth hormone deficiency diagnoses. Strategic partnerships, product innovation, and regulatory approvals remain key competitive factors, as companies strive to enhance patient compliance and capture greater market share in a growing but tightly regulated therapeutic area.

Key Players

  • AnkeBio Co., Ltd
  • Ascendis Pharma
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ferring Pharmaceuticals
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sandoz Inc.
  • Teva Pharmaceuticals USA, Inc.

Industry Developments

July 2025, Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD), a rare disorder resulting from decreased or total loss of growth hormone production.

July 2025, Eli Lilly and Company successful completed the acquisition of Verve Therapeutics, Inc. Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Human Growth Hormone Market Segmentation

By Type Outlook (Revenue, USD Billion, 2021–2034)

  • Long-acting
  • Short-acting & Intermediate-acting

By Route of Administration Outlook (Revenue, USD Billion, 2021–2034)

  • Oral
  • Parenteral
    • Intravenous
    • Subcutaneous
    • Intramuscular

By Age Outlook (Revenue, USD Billion, 2021–2034)

  • Pediatric
  • Adult

By Disease Outlook (Revenue, USD Billion, 2021–2034)

  • Growth Hormone Deficiency
    • Pediatric GHD
    • Adult GHD
  • Turner Syndrome
  • Idiopathic Short Stature
  • Prader-Willi Syndrome
  • Others

By Distribution Channel Outlook (Revenue, USD Billion, 2021–2034)

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Regional Outlook (Revenue, USD Billion, 2021–2034)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Netherlands
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Malaysia
    • South Korea
    • Indonesia
    • Australia
    • Vietnam
    • Rest of Asia Pacific
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America

Human Growth Hormone Market Report Scope

Report Attributes

Details

Market Size in 2024

USD 6.49 Billion

Market Size in 2025

USD 6.98 Billion

Revenue Forecast by 2034

USD 14.51 Billion

CAGR

8.4% from 2025 to 2034

Base Year

2024

Historical Data

2021–2023

Forecast Period

2025–2034

Quantitative Units

Revenue in USD Billion and CAGR from 2025 to 2034

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends

Segments Covered
  • By Type
  • By Route of Administration
  • By Age
  • By Disease
  • By Distribution Channel

Regional Scope
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape
  • Human Growth Harmone Industry Trend Analysis (2024)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format
  • PDF + Excel

Customization

Report customization as per your requirements with respect to countries, regions, and segmentation.

FAQ's

The global market size was valued at USD 6.49 billion in 2024 and is projected to grow to USD 14.51 billion by 2034.

The global market is projected to register a CAGR of 8.4% during the forecast period.

North America dominated the market in 2024

A few of the key players in the market are AnkeBio Co., Ltd; Ascendis Pharma; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Ferring Pharmaceuticals; Merck KGaA; Novo Nordisk A/S; Pfizer Inc; Sandoz Inc.; Teva Pharmaceuticals USA, Inc.

The long-acting segment dominated the market revenue share in 2024.

The online pharmacy segment is projected to witness the fastest growth during the forecast period.

© 2025 Polaris Market Research and Consulting. All rights reserved

paypal